Remove Competition Remove Manufacturing Remove Pharma Remove Prescription
article thumbnail

Pharma is “big business” that uses excuses to keep prices high

World of DTC Marketing

Seventy-nine percent of Americans think the price of prescription drugs is “unreasonable,” according to a 2019 Kaiser Family Foundation poll , and about 9 in 10 say they support the idea of the government negotiating prices. Big Pharma’s chokehold around the U.S. Via Axios “The 10 highest-selling drugs in the U.S.

Pharma 241
article thumbnail

Should we be worried about pharma’s supply chain?

World of DTC Marketing

QUICK READ: Pharma supply chain issues are a concern for us all but especially patients. Hedley Rees has written a book on pharma supply chains that is eye-opening and downright scary. Can patients really be confident in pharma supply chains? Why would a pharma company take risks like these? Patients should be scared.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Pharma says VPAS clawback jeopardises UK sector

pharmaphorum

A pharma industry organisation has warned that record levels of revenue clawback from the UK government is threatening “footprint, R&D and manufacturing investments” in the country. Next year we must start again with a clean sheet of paper to agree on what an internationally competitive scheme looks like.”

Pharma 70
article thumbnail

US legislative update: takeaways for European pharma

European Pharmaceutical Review

In the current US Congressional session, Congress has focused heavily on legislation directed at reducing prescription drug prices. The new law will also require drug manufacturers to pay rebates to Medicare if they increase drug prices faster than consumer inflation. 5) monitoring access to biosimilars.

article thumbnail

Navigating the Challenges of Biopharma Product Launches: A Blueprint for Success

PM360

The landscape is highly competitive with new prescription medications launching worldwide each year. Early shaping of the label during clinical trial design, risk mitigation, and avoiding approval delays are crucial for seizing a competitive advantage.

article thumbnail

Nine for 2023, part three: thriving or surviving?

pharmaphorum

In this final instalment of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry this year, three key competitive issues for pharmaceutical companies in 2023 are assessed. Medicines manufacturing is energy intensive.

article thumbnail

Two Key Questions About Payer Strategies in 2023

PM360

However, we expect drugs without strong therapeutic alternatives to have an advantage in negotiations, while drugs in highly competitive classes will be negotiating from a weaker position. In the near term, manufacturers may need to reconsider price increase strategy given inflation penalties for Medicare beneficiaries.